Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase

Ivan Munoz, Michael Morgan, Julien Peltier, Florian Weiland, Mateusz Gregorczyk, Fiona C. M. Brown, Thomas Macartney, Rachel Toth, Matthias Trost (Lead / Corresponding author), John Rouse (Lead / Corresponding author)

Research output: Contribution to journalArticle

3 Citations (Scopus)
91 Downloads (Pure)

Abstract

Mutations in the gene encoding the protein kinase CDKL5 cause a debilitating neurodevelopmental disease termed CDKL5 disorder. The impact of these mutations on CDKL5 function is poorly understood because the substrates and cellular processes controlled by CDKL5 are unclear. Here, we describe a quantitative phosphoproteomic screening which identified MAP1S, CEP131 and DLG5—regulators of microtubule and centrosome function—as cellular substrates of CDKL5. Antibodies against MAP1S phospho-Ser 900 and CEP131 phospho-Ser 35 confirmed CDKL5-dependent phosphorylation of these targets in human cells. The phospho-acceptor serine residues in MAP1S, CEP131 and DLG5 lie in the motif RPXSA, although CDKL5 can tolerate residues other than Ala immediately C-terminal to the phospho-acceptor serine. We provide insight into the control of CDKL5 activity and show that pathogenic mutations in CDKL5 cause a major reduction in CDKL5 activity in vitro and in cells. These data reveal the first cellular substrates of CDKL5, which may represent important biomarkers in the diagnosis and treatment of CDKL5 disorder, and illuminate the functions of this poorly characterized kinase.

Original languageEnglish
Article numbere99559
Pages (from-to)1-19
Number of pages19
JournalThe EMBO Journal
Volume37
Issue number24
Early online date28 Sep 2018
DOIs
Publication statusPublished - 14 Dec 2018

Fingerprint

Screening
Phosphotransferases
Serine
Mutation
Substrates
Centrosome
Phosphorylation
Gene encoding
Biomarkers
Microtubules
Protein Kinases
Cells
Antibodies
Proteins

Keywords

  • CDKL5 disorder
  • centrosome
  • cilia
  • kinase
  • microtubule

Cite this

Munoz, Ivan ; Morgan, Michael ; Peltier, Julien ; Weiland, Florian ; Gregorczyk, Mateusz ; Brown, Fiona C. M. ; Macartney, Thomas ; Toth, Rachel ; Trost, Matthias ; Rouse, John. / Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. In: The EMBO Journal. 2018 ; Vol. 37, No. 24. pp. 1-19.
@article{549dd8752fe046719fdf4c431a3af96f,
title = "Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase",
abstract = "Mutations in the gene encoding the protein kinase CDKL5 cause a debilitating neurodevelopmental disease termed CDKL5 disorder. The impact of these mutations on CDKL5 function is poorly understood because the substrates and cellular processes controlled by CDKL5 are unclear. Here, we describe a quantitative phosphoproteomic screening which identified MAP1S, CEP131 and DLG5—regulators of microtubule and centrosome function—as cellular substrates of CDKL5. Antibodies against MAP1S phospho-Ser 900 and CEP131 phospho-Ser 35 confirmed CDKL5-dependent phosphorylation of these targets in human cells. The phospho-acceptor serine residues in MAP1S, CEP131 and DLG5 lie in the motif RPXSA, although CDKL5 can tolerate residues other than Ala immediately C-terminal to the phospho-acceptor serine. We provide insight into the control of CDKL5 activity and show that pathogenic mutations in CDKL5 cause a major reduction in CDKL5 activity in vitro and in cells. These data reveal the first cellular substrates of CDKL5, which may represent important biomarkers in the diagnosis and treatment of CDKL5 disorder, and illuminate the functions of this poorly characterized kinase.",
keywords = "CDKL5 disorder, centrosome, cilia, kinase, microtubule",
author = "Ivan Munoz and Michael Morgan and Julien Peltier and Florian Weiland and Mateusz Gregorczyk and Brown, {Fiona C. M.} and Thomas Macartney and Rachel Toth and Matthias Trost and John Rouse",
note = "Medical Research Council (GrantNumber(s): MC_UU_12016/5; Grant recipient(s): Julien Peltier); Loulou Foundation",
year = "2018",
month = "12",
day = "14",
doi = "10.15252/embj.201899559",
language = "English",
volume = "37",
pages = "1--19",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "EMBO Press",
number = "24",

}

Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. / Munoz, Ivan; Morgan, Michael; Peltier, Julien; Weiland, Florian; Gregorczyk, Mateusz; Brown, Fiona C. M.; Macartney, Thomas; Toth, Rachel; Trost, Matthias (Lead / Corresponding author); Rouse, John (Lead / Corresponding author).

In: The EMBO Journal, Vol. 37, No. 24, e99559, 14.12.2018, p. 1-19.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase

AU - Munoz, Ivan

AU - Morgan, Michael

AU - Peltier, Julien

AU - Weiland, Florian

AU - Gregorczyk, Mateusz

AU - Brown, Fiona C. M.

AU - Macartney, Thomas

AU - Toth, Rachel

AU - Trost, Matthias

AU - Rouse, John

N1 - Medical Research Council (GrantNumber(s): MC_UU_12016/5; Grant recipient(s): Julien Peltier); Loulou Foundation

PY - 2018/12/14

Y1 - 2018/12/14

N2 - Mutations in the gene encoding the protein kinase CDKL5 cause a debilitating neurodevelopmental disease termed CDKL5 disorder. The impact of these mutations on CDKL5 function is poorly understood because the substrates and cellular processes controlled by CDKL5 are unclear. Here, we describe a quantitative phosphoproteomic screening which identified MAP1S, CEP131 and DLG5—regulators of microtubule and centrosome function—as cellular substrates of CDKL5. Antibodies against MAP1S phospho-Ser 900 and CEP131 phospho-Ser 35 confirmed CDKL5-dependent phosphorylation of these targets in human cells. The phospho-acceptor serine residues in MAP1S, CEP131 and DLG5 lie in the motif RPXSA, although CDKL5 can tolerate residues other than Ala immediately C-terminal to the phospho-acceptor serine. We provide insight into the control of CDKL5 activity and show that pathogenic mutations in CDKL5 cause a major reduction in CDKL5 activity in vitro and in cells. These data reveal the first cellular substrates of CDKL5, which may represent important biomarkers in the diagnosis and treatment of CDKL5 disorder, and illuminate the functions of this poorly characterized kinase.

AB - Mutations in the gene encoding the protein kinase CDKL5 cause a debilitating neurodevelopmental disease termed CDKL5 disorder. The impact of these mutations on CDKL5 function is poorly understood because the substrates and cellular processes controlled by CDKL5 are unclear. Here, we describe a quantitative phosphoproteomic screening which identified MAP1S, CEP131 and DLG5—regulators of microtubule and centrosome function—as cellular substrates of CDKL5. Antibodies against MAP1S phospho-Ser 900 and CEP131 phospho-Ser 35 confirmed CDKL5-dependent phosphorylation of these targets in human cells. The phospho-acceptor serine residues in MAP1S, CEP131 and DLG5 lie in the motif RPXSA, although CDKL5 can tolerate residues other than Ala immediately C-terminal to the phospho-acceptor serine. We provide insight into the control of CDKL5 activity and show that pathogenic mutations in CDKL5 cause a major reduction in CDKL5 activity in vitro and in cells. These data reveal the first cellular substrates of CDKL5, which may represent important biomarkers in the diagnosis and treatment of CDKL5 disorder, and illuminate the functions of this poorly characterized kinase.

KW - CDKL5 disorder

KW - centrosome

KW - cilia

KW - kinase

KW - microtubule

UR - http://www.scopus.com/inward/record.url?scp=85054063318&partnerID=8YFLogxK

U2 - 10.15252/embj.201899559

DO - 10.15252/embj.201899559

M3 - Article

VL - 37

SP - 1

EP - 19

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 24

M1 - e99559

ER -